Study identifies colistin resistance drug target

  21 May 2021

A Chinese study led by scientists at Zhejiang University in Hangzhou City has identified a linker of resistance from the mobile colistin resistance gene 3 (MCR-3), which might represent a promising drug target against which to develop small-molecule inhibitors to reverse colistin resistance.

“We are first group to functionally define this linker as a facilitator of MCR-3 colistin resistance,” said study co-leader Youjun Feng, a professor in Department of Pathogen Biology & Microbiology at Zhejiang University School of Medicine.

Antimicrobial resistance (AMR) represents an increasingly serious threat to global public health. Of particular concern is the rapid rise of resistance to colistin, or polymyxin E, the antibiotic of last resort against Gram-negative bacteria, including pneumonia.

“AMR is a major problem in many countries including China. New drug targets are lacking, which might be in part responsible for the poor availability of new antibiotics,” said Feng, who co-led the study with Tingjun Hou, a professor in the College of Pharmaceutical Sciences at Zhejiang University.

Further reading: BioWorld
Author(s): John Fox
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed